Alps Group (ALPS) Files Its Annual Report: Revenue Growth Meets Negative Equity

No stock means anything in isolation. That is especially true when the stock is a post-SPAC biotechnology platform with $0.42 per share, a $69 million market cap, and an annual report that tells two different stories depending on which page you read.

Alps Group Inc (NASDAQ: ALPS) filed its Form 20-F for the fiscal year ended March 31, 2026 on August 6 — five days after the market closed on the filing date, and weeks after announcing a delay. The document arrived with operational highlights on one side and structural red flags on the other. The factor stack does not treat those pages as equally weighty.

The Revenue Line Is the Only Thing Moving in the Right Direction

Revenue growth is the headline Alps Group can point to. The company reported 44% year-over-year revenue growth on the trailing twelve-month basis. For context, FY2025 (ended March 31, 2025) revenue was $3.37 million, up 40.3% from the prior year. The trailing twelve months through September 2025 expanded to $5.57 million. Q2 2026 showed a 31.6% year-over-year revenue increase, outpacing the U.S. health information services industry average of 17.47%.

Growth is real. The question is whether $5.57 million in annual revenue is enough to anchor a publicly traded company when the rest of the factor stack is working against it.

Safety Factor: The Company Has Negative Equity

Here is where the factor read changes. Total equity sits at -$3.23 million. Total liabilities are $10.2 million. Cash on hand is $607,500. The current ratio (current assets divided by current liabilities, a measure of near-term liquidity) is 36%. The quick ratio is 27%.

A current ratio below 100% means the company does not have enough short-term assets to cover its short-term obligations. That is not a margin call waiting to happen — it is a margin call that is already happening in slow motion. The company is relying on continued access to capital markets or equity issuance to fund operations, and at $0.42 per share with 16.6 million shares outstanding, the market is not paying a premium for that option.

Cash Flow: The Bleed Is Widening

Operating cash flow over the trailing twelve months was -$2.58 million. Free cash flow (operating cash flow minus capital expenditures, the cash actually available for the business to deploy) was -$2.63 million. Free cash flow growth year-over-year was -55.5%.

That last number matters more than the headline. Free cash flow did not just stay negative — it got worse. A 44% revenue growth rate paired with a 55% deterioration in cash flow tells you the business is spending more than a dollar of cash to generate every dollar of new revenue. That is a pattern that works only if revenue eventually scales past the burn rate. At $5.57 million in annual revenue and $2.63 million in annual cash burn, the path to breakeven is long and unproven.

Governance: Material Weakness and a Nasdaq Deficiency

The 20-F disclosed a material weakness in internal controls over financial reporting. For the uninitiated, a material weakness means the company's own assessment is that its financial reporting processes cannot prevent or detect a misstatement. It is the most serious classification of internal control deficiency under U.S. public company standards.

That disclosure arrived in the same filing that noted the company's May 19 Nasdaq notification for falling below the $1.00 minimum bid price requirement. The stock has traded between $0.38 and $2.90 over the past 52 weeks. It closed at $0.42 on the filing day.

The company appointed a former Ernst & Young partner to its board in April, which is the kind of governance signal that sounds useful until you look at what it is responding to. Governance upgrades matter most when they precede problems, not when they follow them.

Peer Comparison: No Peer to Speak Of

Even picking generous comparison set members makes Alps Group look like an outlier. Here are the numbers across a small biotech set:

• ALPS: $69M market cap, negative PE, 3.46x price-to-book, no dividend
• Moderna (MRNA): $21.5 billion market cap, negative PE (also unprofitable), 3.18x price-to-book
• Biogen-style peer Biogen (BMY): Not returning on this screen, but established profitable biotechs trade at positive multiples with positive cash flow
• Regeneron (REGN): $79.5 billion market cap, 18.4x PE, 2.51x price-to-book, 0.48% dividend yield

Moderna is the closest structural peer — an unprofitable biotech with a negative PE — but its $21.5 billion market cap reflects a commercial pipeline that has already generated billions in sales. Alps Group's $5.57 million in revenue and negative equity place it in a different category entirely. There is no peer that justifies the 3.46x price-to-book multiple when equity itself is negative.

Operational Activity

The company is not idle. The June launch of a patient-derived organoid program (living 3D cell cultures grown from patient tumor tissue, used to test drug responses before treatment) targets personalized cancer care in Southeast Asia. MyGenome, its sequencing arm, expanded accreditation to include whole genome sequencing under MS ISO 15189:2022 standards. These are real operational moves in a space that matters.

But operational activity is not revenue scale. And revenue scale is not profitability. The factor stack requires more than one link in that chain to be strong before the rating turns constructive.

What the Factor Stack Says

• Valuation: The stock is cheap in dollar terms but has no valuation floor. A negative equity balance means there is no book value to fall back on. The price-to-book of 3.46x is meaningless when the book value is negative — the multiple is not anchoring to anything real.
• Growth: 44% revenue growth is genuine and above the sector average. The growth factor is the only one passing. But the base is tiny — 44% of $5.57 million is $2.45 million.
• Profitability: Not yet in evidence. Negative operating cash flow and free cash flow that is deteriorating by 55% year-over-year.
• Safety: Negative equity, sub-40% current ratio, $607K in cash against $10.2M in liabilities. The safety factor is failing.
• Momentum: The stock is down 52% year-to-date and 86% on a rolling annual basis. The 52-week range of $0.38 to $2.90 shows the market has already priced in substantial deterioration.

Portfolio Role: None

Every stock in a watchlist needs a portfolio role. Alps Group does not have one. It is not a growth sleeve candidate — the revenue base is too small and the cash burn is accelerating. It is not a barbell anchor — the safety profile disqualifies it from the durable-cash-flow end of the barbell. It is not a turnaround play — the material weakness in financial controls and Nasdaq deficiency create structural uncertainty that makes timing a turnaround guesswork rather than analysis.

The factor stack would need two things to change before this gets a rating higher than avoid: evidence that revenue scale can outpace cash burn, and a resolution to the internal control weakness. Neither is visible in the 20-F.

What Would Change the Read

Revenue crossing $10 million annually without further acceleration in cash burn would signal operating leverage starting to work. A restated financial report with the internal control weakness resolved and no recurrence would address the governance factor. Either one would narrow the gap between the growth story and the structural reality. Until then, the 20-F is a document that confirms what the price already says: the market has not found a reason to believe the burn rate ends soon.